Vitamins, Breastmilk HIV Shedding, and Child Health
1 other identifier
observational
771
1 country
1
Brief Summary
The purpose of this study is to analyze stored samples and data collected during the conduct of the study "A Trial of Vitamins in HIV Progression and Transmission" (HD32257). The aims are to examine the effect of vitamin supplementation on HIV infected women during pregnancy on a number of parameters in breastmilk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2004
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 20, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2007
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2007
CompletedAugust 21, 2009
August 1, 2009
2.9 years
September 12, 2005
August 20, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
cell-free viral load and/or cell-associated proviral load in breast milk
Delivery, 3 months, and 6 months after delivery
concentration of vitamins A, B12, and E in breast milk
Delivery, 3 months, and 6 months post-delivery
subclinical mastitis
Delivery, 3 months, and 6 months after delivery
Secondary Outcomes (4)
post-natal mother-to-child transmission of HIV
Delivery, 3 months, and 6 months post-delivery
infant mortality and morbidity from diarrhea
Delivery, 3 months and 6 months after delivery
a.) CCR5 expression in differentiating monocytes and differentiated monocyte-derived macrophages
N/A (in vitro experiment)
HIV-1 replication in differentiating monocytes acutely infected with a subtype C HIV-1 clone, differentiated non-dividing MDMs acutely infected with the HIV-1 MJ4 clone, and differentiated non-dividing MDMs chronically infected with the HIV-1 MJ4 clone.
N/A (in vitro experiment)
Study Arms (4)
Vitamin A
Participants in the in the parent study who had been randomized to receive either Vitamin A alone or multivitamins including vitamin A.
No Vitamin A
Participants in the parent study who were randomized to receive either multivitamins excluding vitamin A, or placebo.
Multivitamins
Participants in the parent study who were randomized to receive multivitamins including vitamin A or multivitamins excluding vitamin A
No Multivitamins
Participants from the parent study who had been randomized to vitamin A alone or placebo
Interventions
30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
Placebo pill taken orally once per day during pregnancy and lactation
Eligibility Criteria
The data and samples used in this study are from HIV-infected pregnant women who participated in the "Trial of Vitamins in HIV Transmission and Progression". Between 1995 and 1997, 1,078 African, HIV positive women who were between gestatopm weeks 12 and 27 were recruited. They were followed until August 2003. This study was conducte among 771 of these women, for whom breast milk samples were available at delivery. There were no differences in baseline characteristics between this subset and the originally randomized group of 1,069.
You may qualify if:
- HIV infected women presenting to antenatal care between 12 and 27 weeks of gestation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Harvard School of Public Health
Boston, Massachusetts, 02115, United States
Related Publications (2)
Villamor E, Koulinska IN, Aboud S, Murrin C, Bosch RJ, Manji KP, Fawzi WW. Effect of vitamin supplements on HIV shedding in breast milk. Am J Clin Nutr. 2010 Oct;92(4):881-6. doi: 10.3945/ajcn.2010.29339. Epub 2010 Aug 25.
PMID: 20739426DERIVEDWebb AL, Aboud S, Furtado J, Murrin C, Campos H, Fawzi WW, Villamor E. Effect of vitamin supplementation on breast milk concentrations of retinol, carotenoids and tocopherols in HIV-infected Tanzanian women. Eur J Clin Nutr. 2009 Mar;63(3):332-9. doi: 10.1038/sj.ejcn.1602929. Epub 2007 Oct 17.
PMID: 17940544DERIVED
Biospecimen
Breast milk samples collected from breast at delivery and at 3 month intervals thereafter.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Eduardo Villamor, MD,DrPH
Harvard School of Public Health (HSPH)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 20, 2005
Study Start
September 1, 2004
Primary Completion
August 1, 2007
Study Completion
August 1, 2007
Last Updated
August 21, 2009
Record last verified: 2009-08